Dataset Information

An Optimization of AAV-82Q-Delivered Rat Model of Huntington's Disease.

ABSTRACT: OBJECTIVE:No optimum genetic rat Huntington model both neuropathological using an adeno-associated virus (AAV-2) vector vector has been reported to date. We investigated whether direct infection of an AAV2 encoding a fragment of mutant huntingtin (AV2-82Q) into the rat striatum was useful for optimizing the Huntington rat model. METHODS:We prepared ten unilateral models by injecting AAV2-82Q into the right striatum, as well as ten bilateral models. In each group, five rats were assigned to either the 2×1012 genome copies (GC)/mL of AAV2-82Q (×1, low dose) or 2×1013 GC/mL of AAV2-82Q (×10, high dose) injection model. Ten unilateral and ten bilateral models injected with AAV-empty were also prepared as control groups. We performed cylinder and stepping tests 2, 4, 6, and 8 weeks after injection, tested EM48 positive mutant huntingtin aggregates. RESULTS:The high dose of unilateral and bilateral AAV2-82Q model showed a greater decrease in performance on the stepping and cylinder tests. We also observed more prominent EM48-positive mutant huntingtin aggregates in the medium spiny neurons of the high dose of AAV2-82Q injected group. CONCLUSION:Based on the results from the present study, high dose of AAV2-82Q is the optimum titer for establishing a Huntington rat model. Delivery of high dose of human AAV2-82Q resulted in the manifestation of Huntington behaviors and optimum expression of the huntingtin protein in vivo.

SUBMITTER: So KH

PROVIDER: S-EPMC7477157 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

An Optimization of AAV-82Q-Delivered Rat Model of Huntington's Disease.

So Kyoung-Ha KH Choi Jai Ho JH Islam Jaisan J Kc Elina E Moon Hyeong Cheol HC Won So Yoon SY Kim Hyong Kyu HK Kim Soochong S Hyun Sang-Hwan SH Park Young Seok YS

Journal of Korean Neurosurgical Society 20200305 5

<h4>Objective</h4>No optimum genetic rat Huntington model both neuropathological using an adeno-associated virus (AAV-2) vector vector has been reported to date. We investigated whether direct infection of an AAV2 encoding a fragment of mutant huntingtin (AV2-82Q) into the rat striatum was useful for optimizing the Huntington rat model.<h4>Methods</h4>We prepared ten unilateral models by injecting AAV2-82Q into the right striatum, as well as ten bilateral models. In each group, five rats were as ...[more]

PMID: 32131152

Similar Datasets

Project description:Our aim was to find an effective treatment for the dysfunction in energy regulation and hypothalamic integrity occurring in many HuntingtonM-bM-^@M-^Ys disease (HD) patients and mouse models. HD is a neurodegenerative disease caused by an expanded CAG repeat and is characterized by mutant huntingtin aggregates, cell death, progressive motor impairment, and cognitive alterations. Changes in neuroendocrine function, body weight, energy metabolism, euglycemia, appetite function, sleep, and gut function can also occur. It is likely that the locus of these alterations is the hypothalamus. Male B6C3-Tg(HD82Gln)81Dbo/J (N171-82Q) mice and age-matched wild-type (WT) mice were used. Transgenic mice were identified by PCR analysis of tail DNA. N171-82Q mice express 82 polyglutamine repeats and display multiple HuntingtonM-bM-^@M-^Ys disease-like symptoms. Either Ex-4 (n=10, 300 M-BM-5L of 0.1 M-BM-5mol/L solution, Bachem, Torrance, CA), the GLP-1-transferrin hybrid molecule (n=10, GLP-1Tf, 1mg/kg), insulin (n=10, 5Units, Lantus) or a saline vehicle treatment (n=10, phosphate buffered saline, PBS; Sigma, St. Louis, MO) was administered by a once-daily subcutaneous injection. Injections were started when animals were pre-symptomatic (2 months of age) and continued for 5 weeks. 3 Mice from each treatment qroup were used for the microarray analysis. RNA was extracted from frozen hypothalamus tissue using 1.0mm glass beads (BioSpec Products, Inc.) in a Precellys 24 Tissue Homogenizer (Bertin Technologies) and Qiagen RNeasy Mini Kits according to manufacturer's specifications. Quality and quantity of the total RNA was checked with the Agilent 2100 bioanalyzer using RNA 6000 Nano chips. The standard Illumina protocol using Illumina TotalPrep RNA Amplification Kit (Ambion; Austin, TX, cat # IL1791) was used to biotin label the aRNA generated and then hybridized to Illumina's Sentrix MouseRef-8 v2 Expression BeadChips (Illumina, San Diego, CA). Arrays were scanned at a resolution of 0.8um using the Beadstation 500 X from Illumina.

Dataset Information

An Optimization of AAV-82Q-Delivered Rat Model of Huntington's Disease.

Publications

An Optimization of AAV-82Q-Delivered Rat Model of Huntington's Disease.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure